Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. Common Stock News
May 27, 2025 - globenewswire.com
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
May 12, 2025 - globenewswire.com
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
Lexeo Therapeutics, Inc. Common Stock Quantitative Score
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Lexeo Therapeutics, Inc. Common Stock Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Lexeo Therapeutics, Inc. Common Stock Financials
Table Compare
Compare LXEO metrics with: | |||
|---|---|---|---|
Earnings & Growth | LXEO | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LXEO | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LXEO | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LXEO | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Lexeo Therapeutics, Inc. Common Stock Income
Lexeo Therapeutics, Inc. Common Stock Balance Sheet
Lexeo Therapeutics, Inc. Common Stock Cash Flow
Lexeo Therapeutics, Inc. Common Stock Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Lexeo Therapeutics, Inc. Common Stock Executives
| Name | Role |
|---|---|
| Mr. R. Nolan Townsend | Chief Executive Officer & Director |
| Dr. Jose Manuel Otero Ph.D. | Chief Technical Officer |
| Dr. Eric Adler M.D. | Chief Medical Officer & Head of Research |
| Ms. Jenny R. Robertson J.D. | Chief Legal Officer |
| Mr. Jordan M. Baumhardt Ph.D. | Vice President of Corporate Development |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. R. Nolan Townsend | Chief Executive Officer & Director | Male | 1981 | 3.74M |
| Dr. Jose Manuel Otero Ph.D. | Chief Technical Officer | 1979 | 2.99M | |
| Dr. Eric Adler M.D. | Chief Medical Officer & Head of Research | 1974 | 2.71M | |
| Ms. Jenny R. Robertson J.D. | Chief Legal Officer | Female | 1975 | 617.9K |
| Mr. Jordan M. Baumhardt Ph.D. | Vice President of Corporate Development | Male | -- |
Lexeo Therapeutics, Inc. Common Stock Insider Trades
| Date | 16 May |
| Name | Townsend Richard Nolan |
| Role | Chief Executive Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 1074 |
| Date | 16 May |
| Name | Adler Eric |
| Role | Chief Medical Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 585 |
| Date | 16 May |
| Name | Robertson Jenny |
| Role | Chief Legal Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 521 |
| Date | 16 May |
| Name | See Tai Sandi |
| Role | Chief Development Officer |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 367 |
| Date | 14 Mar |
| Name | Otero Jose Manuel |
| Role | Chief Technical Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 5720 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 16 May | Townsend Richard Nolan | Chief Executive Officer | Disposed | S-Sale | 1074 |
| 16 May | Adler Eric | Chief Medical Officer | Disposed | S-Sale | 585 |
| 16 May | Robertson Jenny | Chief Legal Officer | Disposed | S-Sale | 521 |
| 16 May | See Tai Sandi | Chief Development Officer | Disposed | S-Sale | 367 |
| 14 Mar | Otero Jose Manuel | Chief Technical Officer | Acquired | A-Award | 5720 |